As GLP-1 receptor agonists drive unprecedented weight loss, patients are achieving goal weights but face new aesthetic concerns
Combination therapies Besides the combination therapies described above, in patients with bridging fibrosis and cirrhosis, combining cilofexor (ACC inhibitor) and firsocostat (FXR agonist) for 48 weeks was well tolerated, showed beneficial effects on MASH disease parameters, and might improve fibrosis
These molecules can trigger the release of two hormones linked to curbing hunger: GLP-1 and PYY (peptide YY)
The purified brains were imaged with a LiTonexL thin-section microscope (LiTonexL, Light Innovation Technology, China) with a 4 objective (numerical aperture [NA] 0.28, working distance [WD] 20 mm)
More serious but less common adverse effects include pancreatitis, gallbladder disease, and hypoglycemia (particularly when combined with insulin or sulfonylureas)